StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Pheniramin

Pheniramine

HCID 4761
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
86-21-5
Standard-SMILES
CN(C)CCC(c1ccccc1)c1ccccn1
InChIKey
IJHNSHDBIRRJRN-UHFFFAOYSA-N
Summenformel
C16H20N2
Durchschnittliche Molmasse
240,34 g/mol
Monoisotopische Masse
240,16264865

Überblick

N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine is a member of pyridines and a tertiary amino compound.

Namen und Bezeichner

Bevorzugter Name
Pheniramine
IUPAC
N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine
Lokaler Name
Pheniramin
Englischer Name
Pheniramine
Summenformel
C16H20N2
Molmasse
240.34

Namen und Synonyme

pheniramineProphenpyridamineTripotonPyriton86-21-5PropheniramineFeniraminaPheniraminumdimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine2-(alpha-(2-Dimethylaminoethyl)benzyl)pyridineNSC-47965134FM9ZZ6M
Weitere Namen anzeigen
AVILMetronTrimetonFeniramineNCI-C60695PHENIRAMINE BASE
2-Pyridinepropanamine, N,N-dimethyl-gamma-phenyl-DTXSID0023454Pyridine, 2-(alpha-(2-(dimethylamino)ethyl)benzyl)-dimethyl(3-phenyl-3-(pyridin-2-yl)propyl)amine(+-)-PheniramineRefChem:860603DTXCID203454D04AA16

Datenbank-Bezeichner

CAS
86-21-5
PubChem CID
4761
DTXSID
DTXSID0023454
ChEMBL
CHEMBL1193
ChEBI
CHEBI:91591
UNII
134FM9ZZ6M
EC Number
201-656-2
Nikkaji
J4.935B

Eigenschaften

Berechnete Struktureigenschaften

XLogP
2,8
Polarare Oberfläche (TPSA)
16,1 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
5
Schwere Atome
18
Formalladung
0
Komplexität
221

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Used in Switzerland
Solubility3.77e-01 g/L
Animal DrugsPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Boiling Point175.00 °C. @ 25.00 mm Hg
Melting Point< 25 °C
Physical DescriptionSolid
Collision Cross Section156.75 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
108 °C · 108 °C
Siedepunkt
13 · bp13 181°; bp2 142°; bp0.5 135°
Dichte
1.0081 · 1.0081

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H300 (97.5%): Fatal if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 2 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Regulatory Information2-Pyridinepropanamine, N,N-dimethyl-.gamma.-phenyl-: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 2-Pyridinepropanamine, N,N-dimethyl-.gamma.-phenyl-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 2 (97.5%)

Toxikologische Informationen

Effects During Pregnancy and Lactation◈ What is pheniramine?

Sicherheitsdaten

wgk
1
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
risk_code
11-23/24/25-39/23/24/25
hazard_code
F,T
safety_code
16-36/37-45
Speicherklasse
3 - Flammable liquids

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 4 Einträge

R - Respiratory system

D - Dermatologicals

QD - Dermatologicals

QR - Respiratory system

PharmacodynamicsPheniramine acts as an antagonist to allergic symptoms stemming from inappropriate histamine release to reduce edema, itching, and redness. The same antihistamine effect also produces sedation by acting in the central nervous system.
Mechanism of Action · 1 Eintrag

Pheniramine competes with histamine for the histamine H1 receptor, acting as an inverse agonist once bound. The reduction in H1 receptor activity is responsible for reduced itching as well as reduced vasodilation and capillary leakage leading to less redness and edema. This can be seen in the suppression of the histamine-induced wheal (swelling) and flare (vasodilation) response. Inverse agonism of the H1 receptor in the CNS is also responsible for the sedation produced by first-generation antihistamines like pheniramine. The binding of pheniramine to H4 receptors, and subsequent inverse agonism, may also contribute to reduced itching by antagonizing inflammation.

Biological Half-LifeThe terminal half-life of pheniramine administered via IV is 8-17 h.
Metabolism/MetabolitesPheniramine undergoes N-dealkylation to N-didesmethylpheniramine and N-desmethylpheniramine.
MeSH Pharmacological Classification · 3 Einträge

Agents, usually topical, that relieve itching (pruritus).

Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Brechungsindex
25 · nD25 1.5519 to 1.5521
Flammpunkt
9.7 °C · 9.7 °C - closed cup
storage temp.
-20 °C · -20°C
Löslichkeit
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
powder to crystal
pka
4.03 · pKa 4.03± 0.08;9.32± 0.06(H2O,t undefined,I=0.30(NaCl)) (Uncertain)
Farbe
White to Almost white
Major Application
clinical testing
InChI
1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3
InChIKey
IJHNSHDBIRRJRN-UHFFFAOYSA-N
SMILES
CN(C)CCC(c1ccccc1)c2ccccn2
CAS Datenbank
86 · 86-21-5(CAS DataBase Reference)
NIST chemische Informationen
2 · Pyridine, 2[alpha-(2-dimethyl aminoethyl)benzyl](86-21-5)
Hazard Classifications
Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1

Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)

Absorption, Distribution and Excretion · 2 Einträge

The administration of 30.5 mg of free base pheniramine resulted in a Cmax of 173-294 ng/mL with a Tmax of 1-2.5 h.

Pheniramine is eliminated by metabolism and via renal excretion. 24.3% of pheniramine is present in the urine as the parent drug.

Cellular LocationsMembrane
Metabolite PathwaysPheniramine H1-Antihistamine Action

Verwendung und Herstellung

Use Classification · 2 Einträge

Pharmaceuticals -> Dermatologicals -> Antihistamines

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Potassium amide2-BenzylpyridinMaleinsäure